Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
about
Adjuvants: Classification, Modus Operandi, and LicensingSynthetic Nanoparticles for Vaccines and ImmunotherapyExogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination PostinfluenzaReciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential.Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.Therapeutic strategies based on polymeric microparticles.Invariant NKT cells provide innate and adaptive help for B cells.Differences in physicochemical properties to consider in the design, evaluation and choice between microparticles and nanoparticles for drug delivery.Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses.Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?Mechanisms of Invariant NKT Cell Activity in Restraining Bacillus anthracis Systemic Dissemination.Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.Alpha-galactosylceramide (αGalCer) Enhances Vaccine-induced Protection in a Model of Ricin Intoxication.Therapy of cervical cancer using 131I-labeled nanoparticles.Natural Killer T Cells and Mucosal-Associated Invariant T Cells in Lung InfectionsNanoparticle Vaccines Against Infectious Diseases
P2860
Q26747586-C2B1F88D-DE87-40C7-A004-37AF9F411702Q28085375-EF76D4C0-2713-429E-BC24-EA2E5E2A9039Q30394781-1E83D205-FF77-44D8-8D54-406F99A6ED44Q33720359-78D631EE-4C51-4969-9D25-7A9334A889F3Q36383130-4D41953C-B722-466D-9022-2EFB11CB88BAQ38016146-149A2C0C-6DA4-4A5C-BCB2-630FFBEB29EDQ38186944-D3D91F9E-BD59-4896-8159-D9ED080E019AQ38291341-F2C82290-6985-4FBC-B36E-A1CAE5961C3EQ38564323-DB236B37-8F95-4CF7-A597-DF068A0E7145Q38912004-03C0A172-3C93-4CCF-9A68-A86BD979B00DQ39412754-ACEE4D33-63F1-44AC-BE6B-0BF190AD7826Q41139823-5A33FC6A-668F-40F4-9E9E-6993459DCAB6Q52607682-AF3B7C10-699C-4C7D-AF18-46A8F4B54D18Q55439538-38F9B54B-29CA-45EE-BFDB-16AC0DB615E1Q57171137-F42703F8-BBC2-417C-934C-68F628AACA0CQ58583890-8D7AA34C-EF6D-4C91-AC7F-C0979497A542
P2860
Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Activation of invariant Natura ...... oparticles and microparticles.
@en
Activation of invariant Natura ...... oparticles and microparticles.
@nl
type
label
Activation of invariant Natura ...... oparticles and microparticles.
@en
Activation of invariant Natura ...... oparticles and microparticles.
@nl
prefLabel
Activation of invariant Natura ...... oparticles and microparticles.
@en
Activation of invariant Natura ...... oparticles and microparticles.
@nl
P2093
P50
P1476
Activation of invariant Natura ...... oparticles and microparticles.
@en
P2093
Benoit Frisch
Béatrice Heurtault
Christophe Ehret
Elisabeth Werkmeister
Elodie Macho Fernandez
Emilie Bialecki
Fabien Rodriguez
Jiang Chang
Josette Fontaine
Vanessa Krieger
P356
10.1016/J.IJPHARM.2011.04.068
P407
P577
2011-05-14T00:00:00Z